"Treatment"

Recent findings show that the use of cutting-edge immune checkpoint inhibitor therapy (referred to as immunotherapy in this article) has increased rapidly over the past decade in the population of patients with advanced non-small cell lung cancer (NSCLC), but the survival benefit is more pronounced in younger people than in older people, who have limited survival benefit with this therapy.

According to data from a phase 2 trial, the new treatment Tovorafenib resulted in significant tumour shrinkage in 64% of patients with low-grade gliomas in children, a clinical benefit rate of 91%.

The US FDA approved a new treatment for non-small cell lung cancer - Tremelimumab + Durvalumab + platinum-based chemotherapy. The triple combination therapy significantly improves efficacy and patient survival and has a good safety profile.

The trial is testing the effectiveness of two chemotherapy drugs, oxaliplatin and gemcitabine, in combination with radiotherapy, an approach that has been used to treat other aggressive tumours

Approval for new FIC depression drug on the horizon!

Pancreatic cancer has long been known as the "king of cancers" due to its poor prognosis. However, a recent study showed that adding Mitazalimab to a modified FOLFIRINOX regimen resulted in control of over 90% of patients with metastatic pancreatic cancer, with 52% of patients experiencing significant tumour shrinkage!

Bladder cancer is one of the common diseases nowadays. The incidence of cancer is still very high and many people are affected by cancer, so some bladder cancer patients want to know if the disease is hereditary

Speaking of halitosis, my mind immediately flashed a scene like this: the doorbell rang, and he was anxious to wait for his girlfriend to come. He hurriedly told the parrot a few words. Unexpectedly, the parrot was stunned by his halitosis, fell down and shouted, "You have bad breath! You have bad breath!" Funny aside, you may ask: What causes halitosis? What's the best way to eliminate bad breath?

A new clinical trial update shows that oxitinib (known as Teresa, or 9291) nearly doubled disease-free survival and halved post-operative recurrence rates in lung cancer patients carrying an early stage EGFR mutation!

Preoperative oxaliplatin-fluoropyrimidine chemotherapy given to colon cancer patients did not increase the risk of perioperative complications in colon cancer patients and did reduce postoperative recurrence rates, according to the results of the international phase 3/4 FOxTROT trial.